About lurbinectedin
Alkylating antineoplastic agent
Used for
- Treatment of metastatic small-cell lung cancer after progression on platinum-based chemotherapy.
Usual adult dose
3.2 mg/m² intravenously over 60 minutes every 21 days, until progression or unacceptable toxicity.
Common side effects
- Low blood cell counts
- Nausea and vomiting
- Fatigue
- Abnormal liver tests
Important warnings
- Can cause severe bone marrow suppression and serious infections.
- Can cause liver injury; liver tests are monitored during treatment.
- Serious tissue injury may occur if the infusion leaks outside the vein.
- Avoid strong or moderate CYP3A inhibitors and inducers when possible.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for six months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for two weeks after the final dose.
Interactions
- Strong or moderate CYP3A inhibitors may increase lurbinectedin exposure and toxicity.
- Strong or moderate CYP3A inducers may reduce lurbinectedin exposure and effectiveness.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.